AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Question
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Direct answer
HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market. — bullish pressure on HCM.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-29
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer”, revision 1, evidence through 2026-09-29. https://marketontology.com/catalysts/2026-09-29/astrazeneca-and-hutchmed-submit-us-nda-for-orpathys-plus-tagrisso-in-lung-cancer-a91661
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market. — bullish pressure on HCM.
HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.
- SummaryHUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.
- HCMDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- HCM closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- HCM price vs. pre-event level
- HCM volume vs. 20-day average
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market. — bullish pressure on AZN.
HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.
- SummaryHUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.
- AZNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AZN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AZN price vs. pre-event level
- AZN volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| HCM | Bullishagreed | 14.15 2026-09-29 | +3.39% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaHCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.